New Staff Appointment – Dr Christopher Chan

BioCurate is very pleased to announce Dr Christopher Chan’s appointment as Project Leader.

BioCurate is focused on turning discoveries into therapeutics, and is building a team of highly-experienced individuals capable of working collaboratively to ensure the company’s success.

Dr Chan brings specialised expertise in a fast growing field of research and therapeutic development, with experience in therapeutic antibody development, immuno-oncology, inflammation, innate myeloid and lymphocyte biology, and T cell biology. With this, Chris brings a complementary and highly valuable skill-set to the BioCurate team as the company progresses to expand its involvement in new projects. Together with his colleagues, Chris will manage the development of the BioCurate portfolio from initial academic interaction through delivery of specific project milestones and assist with building the understanding of, and capability in, translational research and the process of early commercial drug development. 

Dr Chan has worked in both start-up and small biotechnology companies in San Francisco, and has experience working in science and technology accelerators, incubators, and leading drug development programs that have led to successful venture capital investments. Chris has led first-in-class antibody development programs from target discovery through to IND-enabling activities, which has culminated in IND approvals by the US FDA, and the submission and granting of numerous patents.

We are delighted that he has decided to join the BioCurate team!

Dr Christopher Chan will commence in his new role on 25 March 2019.